You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis
SBC: KAPS BIOTECHNOLOGY LLC Topic: 102Abstract Prostate cancerCaPis the most common non skin cancer in men and third most common cause of cancer deaths in menBlack men experience a higher burden of incidence and mortality from CaP compared to White menThe Prostate Specific AntigenPSAtesta commonly used biomarker for early diagnosis and management of CaPcannot alone accurately predict the presence of CaPits aggressivenessor the risk of ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Continuous emulsion digital PCR (cdPCR) for low-cost, rapid, near point-of-care genotyping of non-small cell lung cancer
SBC: DropWorks, Inc. Topic: 102PROJECT SUMMARY Genotyping of cancer has become the standard of carewhere specific mutations in cancer driving genes have been shown to indicate sensitivity or resistance to targeted treatmentsSampling of cell free DNAcfDNAin blood plasma could provide a non invasive means of performing this genotypingbut current methods are too complexslowdaysand expensivehundreds of dollarsto make use of this in ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS
SBC: RESTORE THERAPEUTICS LLC Topic: NHLBIPROJECT SUMMARYAcute Respiratory Distress SyndromeARDSis a devastating syndrome that afflicts more thanpatients in United States alone and has an unacceptably high mortality rate ofCurrently there are no therapies that address the loss of lung vascular barrier integrityvascular leakage and alveolar flooding that are critical features of ARDS pathobiologyThe PI was the first to demonstrate that sph ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Modified RNA tools and diagnostics for drug abuse
SBC: ATHGHIN BIOTECHNOLOGY, INC. Topic: NIDADESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Oxidation-resistant Anti-protease Therapy
SBC: LEXEO Therapeutics LLC Topic: NHLBIAbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Innovative, Multifunctional Layered Coatings for High Temperature Ceramic Matrix Composites
SBC: RELIACOAT TECHNOLOGIES, LLC Topic: 18aThe design and realization of thermal/environmental barrier coatings systems for the protection and insulation of ceramic matrix composites that can withstand combustion temperatures approaching 3100 Fahrenheit is a formidable challenge. But that is necessary for achieving 65% efficiency target in future combined-cycle gas-turbine engines. A multifaceted research program is proposed to address thi ...
STTR Phase I 2018 Department of Energy -
STTR Phase I: High-Performance Windows for Daylighting
SBC: SUNTHRU LLC Topic: MIThe broader impacts/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is in the development of energy-saving window products that are aesthetically pleasing. Aerogel window products have the potential to be transformative to the fenestration industry, due both to the high translucency and low thermal conductivity of the aerogel materials and the particular adva ...
STTR Phase I 2014 National Science Foundation -
Imaging Biomarkers of Severe Respiratory Infections in Premature Infants
SBC: KITWARE INC Topic: NHLBIABSTRACTPrematurity is the largest single cause of death in children under five in the world and lower respiratory tract infectionsLRTIare the top cause of hospitalization and mortality in premature infantsClinical tools to predict and prevent severe LRTI in premature pediatric patients are critically needed to allow early interventions to decrease the high morbidity and mortality in this patient ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Image-guided planning system for skull correction in children with craniosynostos
SBC: KITWARE INC Topic: NICHDDESCRIPTION (provided by applicant): Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in 2000 live births. It results in cranial malformation that can lead to elevated intra-cranial pressure, brain growth impairment, and developmental deficiency. The most common treatment option for craniosynostosis is surgery. Currently, surgical treatment planning of cr ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Genome-wide CRISPR screen to identify pro-myogenic factors for cell therapy of DMD
SBC: MYOFINITY BIOSCIENCES INC Topic: NIAMSProject Abstract Myos Incis developing a cell therapy treatment for patients with Duchenne muscular dystrophyDMDbased on HLA matched donor cells that are pretreated with small molecule cocktails ex vivo to modify genes that will enhance engraftment and fusion and enable muscle regenerationMyos is collaborating with DrLouis KunkelBoston Children s Hospitalto address the issues that led to low effic ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health